Systemic Treatment of Diabetic Retinopathy: Glycemic Control and Metabolic Risk Reduction

Diabetic retinopathy is a progressive microvascular complication of diabetes. Slowing its progression depends on sustained, evidence-based systemic medical management, healthy lifestyle, and timely ophthalmological evaluation and care.

Primary Clinical Goal

The central measurable target is achieving an HbA1c of 7% or lower in most patients, with a lower target of 6.5% considered appropriate in selected individuals.

Treatment Approach

Management involves systemic medical therapy and lifestyle intervention addressing multiple metabolic risk factors — including glycemic control, blood pressure, and serum lipid management. The complete structured protocol details the specific agents, monitoring parameters, and clinical decision points.

Instant Access to Structured Evidence-Based Regimens

References

Management of DR includes following a healthy diet and lifestyle, medical management, timely ophthalmic evaluation, and treatment by an ophthalmologist.
It is recommended that a HbA1c of 7% or lower is the target for glycemic control in most patients, whereas in selected patients, there may be some benefit to setting a lower target of 6.5%.
Treatment of hypertension remains important.
Large studies have suggested that managing serum lipids may reduce retinopathy progression and the need for treatment.

View source ↗